Drug Approval | March 25, 2022
USFDA approves Janssen’s injectable regimen for HIV
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Subscribe To Our Newsletter & Stay Updated
